Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy

Experimental Neurology

Volumn 279, Issue , 2016, Pages 13-26

  Butchbach, Matthew E R ^a,b,c,d   Lumpkin, Casey J ^b,d   Harris, Ashlee W ^b   Saieva, Luciano ^e,g   Edwards, Jonathan D ^a   Workman, Eileen ^a,e   Simard, Louise R ^f   Pellizzoni, Livio ^e   Burghes, Arthur H M ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF DELAWARE   (United States)

^e NewYork Presbyterian Hospital   (United States)

^f UNIVERSITY OF MANITOBA   (Canada)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

4 phenylbutyrate; Akt; Butyrate prodrug; Neuroprotection; Preclinical drug trial; Spinal muscular atrophy

Indexed keywords

4 PHENYLBUTYRIC ACID; BUTYRIC ACID; BUTYRIC ACID DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE DEACETYLASE; PRODRUG; PROTEIN KINASE B; SURVIVAL MOTOR NEURON PROTEIN 2; TRIBUTYRIN; UNCLASSIFIED DRUG; VX 563; GLYCOGEN SYNTHASE KINASE 3; GSK3B PROTEIN, MOUSE; HISTONE DEACETYLASE INHIBITOR; NEUROPROTECTIVE AGENT; ONCOPROTEIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG TISSUE LEVEL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GROWTH RATE; IN VIVO STUDY; LIFESPAN; MOUSE; NEUROPROTECTION; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SPINAL CORD; SPINAL MUSCULAR ATROPHY; SURVIVAL; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; FEMALE; GROWTH, DEVELOPMENT AND AGING; KNOCKOUT MOUSE; MALE; METABOLISM; MOTONEURON; MUSCULAR ATROPHY, SPINAL; PATHOLOGY; PHOSPHORYLATION; PSYCHOLOGY;

ANIMALS; BEHAVIOR, ANIMAL; BUTYRATES; CELL SURVIVAL; FEMALE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HISTONE DEACETYLASE INHIBITORS; MALE; MICE; MICE, KNOCKOUT; MOTOR NEURONS; MUSCULAR ATROPHY, SPINAL; NEUROPROTECTIVE AGENTS; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PRODRUGS; SPINAL CORD;

EID: 84958787133     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2016.02.009     Document Type: Article

References (127)

1. Andreassi C., Angelozzi C., Tiziano F.D., Vitali T., De Vincenzi E., Boninsegna A., Villanova M., Bertini E., Pini A., Neri G., Brahe C. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur. J. Hum. Genet. 2004, 12:59-65.
2. Avila A.M., Burnett B.G., Taye A.A., Gabanella F., Knight M.A., Hartenstein P., Cizman Z., DiProspero N.A., Pellizzoni L., Fischbeck K.H., Sumner C.J. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest. 2007, 117:659-671.
3. Berg S., Serabe B., Aleksic A., Bomgaars L., McGuffey L., Dauser R., Durfee J., Nuchtern J., Blaney S. Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate. Cancer Chemother. Pharmacol. 2001, 47:385-390.
4. Bevan A.K., Hutchinson K.R., Foust K.D., Braun L., McGovern V.L., Schmelzer L., Ward J.G., Petruska J.C., Lucchesi P.A., Burghes A.H.M., Kaspar B.K. Early heart failure in the SMNδ7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum. Mol. Genet. 2010, 19:3895-3905.
5. Biondi O., Branchu J., Sanchez G., Lancelin C., Deforges S., Lopes P., Pariset C., Lécolle S., Côté J., Chanoine C., Charbonnier F. In vivo NMDA receptor activation accelerates motor unit maturation, protects spinal motor neurons and enhances SMN2 gene expression in severe spinal muscular atrophy mice. J. Neurosci. 2010, 30:11288-11299.
6. Biondi O., Lopes P., Desseille C., Branchu J., Chali F., Ben Salah A., Pariset C., Chanoine C., Charbonnier F. Physical exercise reduces cardiac defects in type 2 spinal muscular atrophy-like mice. J. Physiol. 2012, 590:5907-5925.
7. Biondi O., Branchu J., Ben Salah A., Houdebine L., Bertin L., Chali F., Desseille C., Weill L., Sanchez G., Lancelin C., Aïd S., Lopes P., Pariset C., Lécolle S., Côté J., Holzenberger M., Chanoine G., Massaad C., Charbonnier F. IGF-1R reduction triggers neuroprotective signaling pathways in spinal muscular atrophy mice. J. Neurosci. 2015, 35:12063-12079.
8. Boffa L.C., Vidali G., Mann R.S., Allfrey V.G. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J. Biol. Chem. 1978, 253:3364-3366.
9. Bowerman M., Beauvais A., Anderson C.L., Kothary R. Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. Hum. Mol. Genet. 2010, 19:1468-1478.
10. Brahe C., Vitali T., Tiziano F.D., Angelozzi C., Pinto A.M., Borgo F., Moscato U., Bertini E., Mercuri E., Neri G. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur. J. Hum. Genet. 2005, 13:256-259.
11. Branchu J., Biondi O., Chali F., Collin T., Leroy F., Mamchaoui K., Makoukji J., Pariset C., Lopes P., Massaad C., Chanoine C., Charbonnier F. Shift from extracellular signal-related kinase to AKT/cAMP response element-binding protein pathway increases survival-motor-neuron expression in spinal-muscular-atrophy-like mice and patient cells. J. Neurosci. 2013, 33:4280-4294.
12. Brichta L., Hofmann Y., Hahmen E., Siebzehnrubl F.A., Raschke H., Blumcke I., Eyupoglu I.Y., Wirth B. Valproic acid increases the SMN2 protein level: a well-known drug as potential therapy for spinal muscular atrophy. Hum. Mol. Genet. 2003, 12:2481-2489.
13. Brichta L., Holker I., Haug K., Klockgether T., Wirth B. In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann. Neurol. 2006, 59:970-975.
14. Butchbach M.E.R., Edwards J.D., Burghes A.H.M. Abnormal motor phenotype in the SMNδ7 mouse model of spinal muscular atrophy. Neurobiol. Dis. 2007, 27:207-219.
15. Butchbach M.E.R., Edwards J.D., Schussler K.R., Burghes A.H.M. A novel method for oral delivery of compounds to the neonatal SMNδ7 model of spinal muscular atrophy. J. Neurosci. Methods 2007, 161:285-290.
16. Butchbach M.E.R., Rose F.F., Rhoades S., Marston J., McCrone J.T., Sinnott R., Lorson C.L. Effect of diet on the survival and phenotype of a mouse model for spinal muscular atrophy. Biochem. Biophys. Res. Commun. 2010, 391:835-840.
17. Butchbach M.E.R., Singh J., orsteindóttir M., Saieva L., Slominski E., Thurmond J., Andrésson T., Zhang J., Edwards J.D., Simard L.R., Pellizzoni L., Jarecki J., Burghes A.H.M., Gurney M.E. Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum. Mol. Genet. 2010, 19:454-467.
18. Butchbach M.E.R., Singh J., Gurney M.E., Burghes A.H.M. The effect of diet on the protective action of D156844 observed in spinal muscular atrophy mice. Exp. Neurol. 2014, 256:1-6.
19. Chang J.G., Hsieh-Li H.M., Jong Y.J., Wang N.M., Tsai C.H., Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:9808-9813.
20. Chen P.C., Gasisina I.N., El-Khodor B.F., Ramboz S., Makhortova N.R., Rubin L.L., Kozikowski A.P. Identification of a maleimide-based glycogen synthase kinase-3 (GSK-3) inhibitor, BIP-135, that prolongs the median survival time of δ7 SMA KO mouse model of spinal muscular atrophy. ACS Chem. Neurosci. 2012, 3:5-11.
21. Cherry J.J., Osman E.Y., Evans M.C., Choi S., Xing X., Cuny G.D., Glicksman M.A., Lorson C.L., Androphy E.J. Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds. EMBO Mol. Med. 2013, 5:1103-1118.
22. Chuang D.M., Leng Y., Marinova Z., Kim H.J., Chiu C.T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009, 32:591-601.
23. Cifuentes-Diaz C., Nicole S., Velasco M.E., Borra-Cebrian C., Panozzo C., Frugier T., Millet G., Roblot N., Joshi V., Melki J. Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse model. Hum. Mol. Genet. 2002, 11:1439-1447.
24. Conley B.A., Egorin M.J., Tait N., Rosen M., Sausville E.A., Dover G., Fram R.J., Van Echo D.A. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin. Cancer Res. 1998, 4:629-634.
25. Coovert D.D., Le T.T., McAndrew P.E., Strasswimmer J., Crawford T.O., Mendell J.R., Coulson S.E., Androphy E.J., Prior T.W., Burghes A.H.M. The survival motor neuron protein in spinal muscular atrophy. Hum. Mol. Genet. 1997, 6:1205-1214.
26. Davis T., Kennedy C., Chiew Y.E., Clarke C.L., deFazio A. Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin. Cancer Res. 2000, 6:4334-4342.
27. Del Signore S.J., Amante D.J., Kim J., Stack E.C., Goodrich S., Cormier K., Smith K., Cudkowicz M.E., Ferrante R.J. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph. Lateral Scler. 2009, 10:85-94.
28. DiDonato C.J., Chen X.N., Noya D., Korenberg J.R., Nadeau J.H., Simard L.R. Cloning, characterization and copy number of the murine survival motor neuron gene: homolog of the spinal muscular atrophy-determining gene. Genome Res. 1997, 7:339-352.
29. Dominguez E., Marais T., Chatauret N., Benkhelifa-Ziyyat S., Duque S., Ravassard P., Carcenac R., Astord S., Pereira de Moura A., Voit T., Barkats M. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum. Mol. Genet. 2011, 20:681-693.
30. Edelman M.J., Bauer K., Khanwani S., Tait N., Trepel J., Karp J., Nemieboka M., Chung E.J., Van Echo D. Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug. Cancer Chemother. Pharmacol. 2003, 51:439-444.
31. Egorin M.J., Yuan Z.M., Sentz D.L., Plaisance K., Eiseman J.L. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Cancer Chemother. Pharmacol. 1999, 43:445-453.
32. Elsheikh B., Prior T., Zhang X., Miller R., Kolb S.J., Moore D., Bradley W., Barohn R., Bryan W., Gelinas D., Iannaccone S., Leshner R., Mendell J.R., Mendoza M., Russman B., Smith S., King W., Kissel J.T. An analysis of disease severity based on SMN2 copy number in adults with spinal muscular atrophy. Muscle Nerve 2009, 40:652-656.
33. Ferrante R.J., Kubilus J.K., Lee J., Ryu H., Beesen A., Zucker B., Smith K., Kowall N.W., Ratan R.R., Luthi-Carter R., Hersch S.M. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 2003, 23:9418-9427.
34. Foust K.D., Wang X., McGovern V.L., Braun L., Bevan A.K., Haidet A.M., Le T.T., Morales P.R., Rich M.M., Burghes A.H.M., Kaspar B.K. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol. 2010, 28:271-274.
35. Gabanella F., Carissimi C., Usiello A., Pellizzoni L. The activity of the spinal muscular atrophy protein is regulated during development and cellular differentiation. Hum. Mol. Genet. 2005, 14:3629-3642.
36. Gabanella F., Butchbach M.E.R., Saieva L., Carissimi C., Burghes A.H.M., Pellizzoni L. Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. PLoS One 2007, 9:e921.
37. Garbes L., Riessland M., Hölker I., Heller R., Hauke J., Tränkle C., Coras R., Blümcke I., Hahnen E., Wirth B. LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Hum. Mol. Genet. 2009, 18:3645-3658.
38. Gardian G., Browne S.E., Choi D.K., Klivenyi P., Gregorio J., Kubilus J.K., Ryu H., Langley B., Ratan R.R., Ferrante R.J., Beal M.F. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 2005, 280:556-563.
39. Gavrilina T.O., McGovern V.L., Workman E., Crawford T.O., Gogliotti R.G., DiDonato C.J., Monani U.R., Morris G.E., Burghes A.H.M. Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle specific SMN expression has no phenotypic effect. Hum. Mol. Genet. 2008, 17:1063-1075.
40. Gogliotti R.G., Cardona H., Singh J., Bail S., Emery C., Kuntz N., Jorgensen M., Durens M., Xia B., Barlow C., Heier C., Plasterer H.L., Jacques V., Kiledjian M., Jarecki J., Rusche J., DiDonato C.J. The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Hum. Mol. Genet. 2013, 22:4084-4101.
41. Hahnen E., Eyüpoglu I.Y., Brichta L., Haastert K., Tränkle C., Siebzehnrübl F.A., Riessland M., Hölker I., Claus P., Romstöck J., Buslei R., Wirth B., Blümcke I. In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J. Neurochem. 2006, 98:193-202.
42. Harahap I.S.K., Saito T., San L.P., Sasaki N., Gunadi, Nurputra D.K.P., Yusoff S., Yamamoto T., Morikawa S., Nishimura N., Lee M.J., Takeshima Y., Matsuo M., Nishio H. Valproic acid increases SMN2 expression and modulates SF2/ASF and hnRNPA1 expression in SMA fibroblast cell lines. Brain Dev. 2012, 34:213-222.
43. Harris A.W., Butchbach M.E.R. The effect of the DcpS inhibitor D156844 on the protective action of follistatin in mice with spinal muscular atrophy. Neuromuscul. Disord. 2015, 25:699-705.
44. Heier C.R., DiDonato C.J. Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function of SMA mice in vivo. Hum. Mol. Genet. 2009, 18:1310-1322.
45. Heier C.R., Satta R., Lutz C., DiDonato C.J. Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Hum. Mol. Genet. 2010, 19:3906-3918.
46. Hsieh-Li H.M., Chang J.G., Jong Y.J., Wu M.H., Wang N.M., Tsai C.H., Li H. A mouse model for spinal muscular atrophy. Nat. Genet. 2000, 24:66-70.
47. Hua Y., Sahashi K., Hung G., Rigo F., Passini M.A., Bennett C.F., Krainer A.R. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 2010, 24:1634-1644.
48. Hua Y., Sahashi K., Rigo F., Hung G., Horev G., Bennett C.F., Krainer A.R. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011, 478:123-126.
49. Hur E.M., Zhou F.Q. GSK3 signalling in neural development. Nat. Rev. Neurosci. 2010, 11:539-551.
50. Iyer C.C., McGovern V.L., Murray J.D., Gombash S.E., Zaworski P.G., Foust K.D., Janssen P.M.L., Burghes A.H.M. Low levels of survival motor neuron protein are sufficient for normal muscle function in the SMNδ7 mouse model of SMA. Hum. Mol. Genet. 2015, 24:6160-6173.
51. Kernochan L.E., Russo M.L., Woodling N.S., Huynh T.N., Avila A.M., Fischbeck K.H., Sumner C.J. The role of histone acetylation in SMN gene expression. Hum. Mol. Genet. 2005, 14:1171-1182.
52. Kuefer R., Hofer M.D., Altug V., Zorn C., Genze F., Kunzi-Rapp K., Hautmann R.E., Gschwend J.E. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br. J. Cancer 2004, 90:535-541.
53. Kye M.J., Niederst E.D., Wertz M.H., Gonçalves IdoCG, Akten B., Dover K.Z., Peters M., Riessland M., Neveu P., Wirth B., Kosik K.S., Sardi S.P., Monani U.R., Passini M.A., Sahin M. SMN regulates axonal local translation via miR-183/mTOR pathway. Hum. Mol. Genet. 2015, 23:6318-6331.
54. Le T.T., Pham L.T., Butchbach M.E.R., Zhang H.L., Monani U.R., Coovert D.D., Gavrilina T.O., Xing L., Bassell G.J., Burghes A.H.M. SMNδ7, the major product of the centromeric survival motor neuron gene (SMN2), extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet. 2005, 14:845-857.
55. Lefebvre S., Bürglen L., Reboullet S., Clermont O., Burlet P., Viollet L., Benichou B., Cruaud C., Millasseau P., Zeviani M., Le Paslier D., Frézal J., Cohen D., Weissenbach J., Munnich A., Melki J. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995, 80:155-165.
56. Lefebvre S., Burlet P., Liu Q., Bertrandy S., Clermont O., Munnich A., Dreyfuss G., Melki J. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Genet. 1997, 16:265-269.
57. Li D.K., Tisdale S., Lotti F., Pellizzoni L. SMN control of RNP assembly: from post-transcriptional gene regulation to motor neuron disease. Semin. Cell Dev. Biol. 2014, 32:22-29.
58. Liu H., Yazdani A., Murray L.M., Beauvais A., Kothary R. The Smn-independent beneficial effects of trichostatin A on an intermediate mouse model of spinal muscular atrophy. PLoS One 2014, 9:e101225.
59. Lorson C.L., Hahnen E., Androphy E.J., Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:6307-6311.
60. Lunke S., El-Osta A. The emerging role of epigenetic modifications and chromatin remodeling in spinal muscular atrophy. J. Neurochem. 2009, 109:1557-1569.
61. Martinez T.L., Kong L., Wang X., Osborne M.A., Crowder M.E., Van Meerbeke J.P., Xu X., Davis C., Wooley J., Goldhamer D.J., Lutz C.M., Rich M.M., Sumner C.J. Survival motor neuron protein in motor neurons determines synaptic integrity in spinal muscular atrophy. J. Neurosci. 2012, 32:8703-8715.
62. Mattis V.B., Ebert A.D., Fosso M.Y., Chang C.W., Lorson C.L. Delivery of a read-through inducing compound, TC007, lessens the severity of a SMA animal model. Hum. Mol. Genet. 2009, 18:3906-3913.
63. Mattis V.B., Fosso M.Y., Chang C.W., Lorson C.L. Sucutaneous administration of TC007 reduces disease severity in an animal model of SMA. BMC Neurosci. 2009, 10:142.
64. Mattis V.B., Chang C.W.T., Lorson C.L. Analysis of a read-through promoting compound in a severe mouse model of spinal muscular atrophy. Neurosci. Lett. 2012, 525:72-75.
65. C gene copy number. Am. J. Hum. Genet. 1997, 60:1411-1422.
66. McCaffrey P.G., Wang Y.C., Newsome D.A., Leon E.J., Li B., Kim E., Tung R., Chaturvedi P., Su M.S.S. Pharmacokinetics and efficacy studies of a new butyrate prodrug for induction of fetal hemoglobin in anemic rhesus monkeys. Blood 1996, 88:1232.
67. McGovern V.L., Iyer C.C., Arnold W.D., Gombash S.E., Zaworski P.G., Blatnik A.J., Foust K.D., Burghes A.H.M. SMN expression is required in motor neurons to rescue electrophysiological deficits in the SMNδ7 mouse model of SMA. Hum. Mol. Genet. 2015, 24:5524-5541.
68. Mentis G.Z., Blivis D., Liu W., Drobac E., Crowder M.E., Kong L., Alvarez F.J., Sumner C.J., O'Donovan M.J. Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy. Neuron 2011, 69:453-467.
69. Mercuri E., Bertini E., Messina S., Pelliccioni M., D'Amico A., Colitto F., Mirabella M., Tiziano F.D., Vitali T., Angelozzi C., Kinali M., Main M., Brahe C. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul. Disord. 2004, 14:130-135.
70. Mercuri E., Bertini E., Messina S., Solari A., D'Amico A., Angelozzi C., Battini R., Berardinelli A., Boffi P., Bruno C., Cini C., Colitto F., Kinali M., Minetti C., Mongini T., Morandi L., Neri G., Orcesi S., Pane M., Pelliccioni M., Pini A., Tiziano F.D., Villanova M., Vita G., Brahe C. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology 2007, 68:51-55.
71. Michaud M., Arnoux T., Bielli S., Durand E., Rotrou Y., Jablonka S., Robert F., Giraudon-Paoli M., Riessland M., Mattei M.G., Andriambeloson E., Wirth B., Sendtner M., Gallego J., Pruss R.M., Bordet T. Neuromuscular defects and breathing disorders in a new mouse model of spinal muscular atrophy. Neurobiol. Dis. 2010, 38:125-135.
72. Mitrpant C., Porensky P., Zhou H., Price L., Muntoni F., Fletcher S., Wilton S.D., Burghes A.H.M. Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy. PLoS One 2013, 8:e62114.
73. Miwa H., Yamamoto M. High-performance liquid chromatographic analysis of serum short-chain fatty acids by direct derivatization. J. Chromatogr. 1987, 421:33-41.
74. Monani U.R., Lorson C.L., Parsons D.W., Prior T.W., Androphy E.J., Burghes A.H.M., McPherson J.D. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet. 1999, 8:1177-1183.
75. Monani U.R., Sendtner M., Coovert D.D., Parsons D.W., Andreassi C., Le T.T., Jablonka S., Schrank B., Rossoll W., Prior T.W., Morris G.E., Burghes A.H.M. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn-/- mice and results in a mouse with spinal muscular atrophy. Hum. Mol. Genet. 2000, 9:333-339.
76. Narver H.L., Kong L., Burnett B.G., Choe D.K., Bosch-Marcé M., Taye A.A., Eckhaus M.A., Sumner C.J. Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition. Ann. Neurol. 2008, 64:465-470.
77. Naryshkin N.A., Weetall M., Dakka A., Narasimhan J., Zhao X., Feng Z., Ling K.K.Y., Karp G.M., Qi H., Woll M.G., Chen G., Zhang N., Gabbeta V., Vazirani P., Bhattacharyya A., Furia B., Risher N., Sheedy J., Kong R., Ma J., Turpoff A., Lee C.S., Zhang X., Moon Y.C., Trifillis P., Welch E.M., Colacino J.M., Babiak J., Almstead N.G., Peltz S.W., Eng L.A., Chen K.S., Mull J.L., Lynes M.S., Rubin L.L., Fontoura P., Santarelli L., Haenke D., McCarthy K.D., Schmucki R., Ebeling M., Sivaramakrishnan M., Ko C.P., Paushkin S.V., Ratni H., Gerlach I., Ghosh A., Metzger F. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 2014, 345:688-693.
78. Nguyen thi Man, Humphrey E., Lam L.T., Fuller J.R., Lynch T.A., Sewry C.A., Goodwin P.R., MacKenzie A.E., Morris G.E. A two-site ELISA can quantify upregulation of SMN protein by drugs for spinal muscular atrophy. Neurology 2008, 71:1757-1763.
79. Nicole S., Desforges B., Millet G., Lesbordes J., Cifuentes-Diaz C., Vertes D., Cao M.L., De Backer F., Languille L., Roblot N., Joshi V., Gillis J.M., Melki J. Intact satellite cells lead to remarkable protection against Smn gene defect in differentiation skeletal muscle. J. Cell Biol. 2003, 161:571-582.
80. Ning K., Drepper C., Valori C.F., Ahsan M., Wyles M., Higginbottom A., Herrmann T., Shaw P., Azzouz M., Sendtner M. PTEN depletion rescues axonal growth defect and improves survival in SMN-deficient motor neurons. Hum. Mol. Genet. 2010, 19:3159-3168.
81. Osman E.Y., Miller M.R., Robbins K.L., Lombardi A.M., Atkinson A.K., Brehm A.J., Lorson C.L. Morpholino antisense oligonucleotides targeting intronic repressor Element1 improve phenotype in SMA mouse models. Hum. Mol. Genet. 2014, 23:4832-4845.
82. Özcan U., Yilmaz E., Özcan L., Furuhashi M., Vaillancourt E., Smith R.O., Görgün C.Z., Hotamisligil G.S. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006, 313:1137-1140.
83. Palacino J., Swalley S.E., Song C., Cheung A.K., Shu L., Zhang X., Van Hoosear M., Shin Y., Chin D.N., Gubser Keller C., Beibel M., Renaud N.A., Smith T.M., Salcius M., Shi X., Hild M., Servais R., Jain M., Deng L., Bullock C., McLellan M., Schuierer S., Murphy L., Blommers M.J.J., Blaustein C., Berenshteyn F., Lacoste A., Thomas J.R., Roma G., Michaud G.A., Tseng B.S., Porter J.A., Myer V.E., Tallarico J.A., Hamann L.G., Curtis D., Fishman M.C., Dietrich W.F., Dales N.A., Sivasankaran R. SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat. Chem. Biol. 2015, 11:511-517.
84. Passini M.A., Bu J., Roskelley E.M., Richards A.M., Sardi S.P., O'Riordan C.R., Klinger K.W., Shihabuddin L.S., Cheng S.H. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J. Clin. Invest. 2010, 120:1253-1264.
85. Passini M.A., Bu J., Richards A.M., Kinnecom C., Sardi S.P., Stanek L.M., Hua Y., Rigo F., Matson J., Hung G., Kaye E.M., Shihabuddin L.S., Krainer A.R., Bennett C.F., Cheng S.H. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med. 2011, 3:72ra18.
86. Petri S., Kiaei M., Kipiani K., Chen J., Calingasan N.Y., Crow J.P., Beal M.F. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2006, 22:40-49.
87. Peviani M., Tortarolo M., Battaglia E., Piva R., Bendotti C. Specific induction of Akt3 in spinal cord motor neurons is neuroprotective in a mouse model of familial amyotrophic lateral sclerosis. Mol. Neurobiol. 2014, 49:136-148.
88. Porensky P.N., Mitrpant C., McGovern V.L., Bevan A.K., Foust K.D., Kaspar B.K., Wilton S.D., Burghes A.H.M. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum. Mol. Genet. 2012, 21:1625-1638.
89. Prior T.W., Swoboda K.J., Scott H.D., Hejmanowski A.Q. Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. Am. J. Med. Genet. 2005, 130A:307-310.
90. Qi X., Hosoi T., Okuma Y., Kaneko M., Nomura Y. Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol. Pharmacol. 2004, 66:899-908.
91. Qin L., Wang Z., Tao L., Wang Y. ER stress negatively regulates AKT/TSC/mTOR pathway to enhance autophagy. Autophagy 2010, 6:239-247.
92. Rahmani M., Yu C., Reese E., Ahmed W., Hirsch K., Dent P., Grant S. Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21CIP1/WAF1 induction rather than AKT inhibition. Oncogene 2003, 22:6231-6242.
93. Renusch S.R., Harshman S., Pi H., Workman E., Wehr A., Li X., Prior T.W., Elsheikh B., Swoboda K.J., Simard L.R., Kissel J.T., Battle D., Parthun M.R., Freitas M.A., Kolb S.J. Spinal muscular atrophy biomarker measurements from blood samples in a clinical trial of valproic acid in ambulatory adults. J. Neuromuscul. Dis. 2015, 2:119-130.
94. Ribobaraza A., Cuadrado-Tejedor M., Pérez-Mediavilla A., Frechilla D., Del Río J., García-Osta A. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 2009, 34:1721-1732.
95. Riessland M., Brichta L., Hahnen E., Wirth B. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum. Genet. 2006, 120:101-110.
96. Riessland M., Ackermann B., Förster A., Jakubik M., Hauke J., Garbes L., Fritzsche I., Mende Y., Blumcke M., Hahnen E., Wirth B. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum. Mol. Genet. 2010, 19:1492-1506.
97. Rodgers E.E., Theibert A.B. Functions of PI 3-kinase in development of the nervous system. Int. J. Dev. Neurosci. 2002, 20:187-197.
98. Rose F.F., Mattis V.B., Rindt H., Lorson C.L. Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy. Hum. Mol. Genet. 2009, 18:997-1005.
99. Ryu H., Smith K., Camelo S.I., Carreras I., Lee J., Iglesias A.H., Dangood F., Cormier K.A., Cudkowicz M.E., Brown R.H., Ferrante R.J. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 2005, 93:1087-1098.
100. Sahashi K., Ling K.K.Y., Hua Y., Wilkinson J.E., Nomakuchi T., Rigo F., Hung G., Xu D., Jiang Y.P., Lin R.Z., Ko C.P., Bennett C.F., Krainer A.R. Pathological impact of SMN2 mis-splicing in adult SMA mice. EMBO Mol. Med. 2013, 5:1586-1601.
101. Schrank B., Götz R., Gunnersen J.M., Ure J.M., Toyka K.V., Smith A.G., Sendtner M. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:9920-9925.
102. Shababi M., Habibi J., Yang H.T., Vale S.M., Sewell W.A., Lorson C.L. Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum. Mol. Genet. 2010, 19:4059-4071.
103. Shababi M., Habibi J., Ma L., Glascock J.J., Sowers J.R., Lorson C.L. Partial restoration of cardio-vascular defects in a rescued severe model of spinal muscular atrophy. J. Mol. Cell. Cardiol. 2012, 52:1074-1082.
104. Simard L.R., Bélanger M.C., Morissette S., Wride M., Prior T.W., Swoboda K.J. Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with SMA. Neurology 2007, 68:451-456.
105. Stabley D.L., Harris A.W., Holbrook J., Chubbs N.J., Lozo K.W., Crawford T.O., Swoboda K.J., Funanage V.L., Wang W., Mackenzie W., Scavina M., Sol-Church K., Butchbach M.E.R. SMN1 and SMN2 copy numbers in cell lines derived from patients with spinal muscular atrophy as measured by array digital PCR. Mol. Genet. Genomic Med. 2015, 3:248-257.
106. Staropoli J.F., Li H., Chun S.J., Allaire N., Cullen P., Thai A., Fleet C.M., Hua Y., Bennett C.F., Krainer A.R., Kerr D., McCampbell A., Rigo F., Carulli J.P. Rescue of gene-expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7. Genomics 2015, 105:220-228.
107. Steffan J.S., Bodai L., Pallos J., Poelman M., McCampbell A., Apostol B.L., Kazantsev A., Schmidt E., Zhu Y.Z., Greenwald M., Kurokawa R., Housman D.E., Jackson G.R., Marsh J.L., Thompson L.M. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413:739-743.
108. Sumner C.J., Huynh T.N., Markowitz J.A., Perhac J.S., Hill B., Coovert D.D., Schussler K., Chen X., Jarecki J., Burghes A.H.M., Taylor J.P., Fischbeck K.H. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann. Neurol. 2003, 54:647-654.
109. Swoboda K.J., Prior T.W., Scott C.B., McNaught T.P., Wride M.C., Reyna S.P., Bromberg M.B. Natural history of denervation in SMA: relation to age, SMN2 copy number and function. Ann. Neurol. 2005, 57:704-712.
110. Swoboda K.J., Scott C.B., Reyna S.P., Prior T.W., LaSalle B., Sorenson S.L., Wood J., Acsadi G., Crawford T.O., Kissel J.T., Krosschell K.J., D'Anjou G., Bromberg M.B., Schroth M.K., Chan G.M., Elsheikh B., Simard L.R. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One 2009, 4:e5268.
111. Thurmond J., Butchbach M.E.R., Palomo M., Pease B., Rao M., Bedell L., Keyvan M., Pai G., Mishra R., Haraldsson M., Andresson T., Bragason G., Thosteinsdottir M., Bjornsson J.M., Coovert D.D., Burghes A.H.M., Gurney M.E., Singh J. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. J. Med. Chem. 2008, 51:449-469.
112. Tisdale S., Pellizzoni L. Disease mechanisms and therapeutic approaches in spinal muscular atrophy. J. Neurosci. 2015, 35:8691-8700.
113. Tiziano F.D., Bertini E., Messina S., Angelozzi C., Pane M., D'Amico A., Alfieri P., Fiori S., Battini R., Berardinelli A., Boffi P., Bruno C., Cini C., Minetti C., Mongini T., Morandi L., Orcesi S., Pelliccioni M., Pini A., Villanova M., Vita G., Locatelli M., Mercuri E., Brahe C. The Hammersmith functional score correlates with the SMN2 copy number: a multicentric study. Neuromuscul. Disord. 2007, 17:400-403.
114. Tsai L.K., Tsai M.S., Ting C.H., Li H. Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice. J. Mol. Med. 2008, 86:1243-1254.
115. Valori C.F., Ning K., Wyles M., Mead R.J., Grierson A.J., Shaw P.J., Azzouz M. Systemic delivery of scAAV9 expressin SMN prolongs survival in a model of spinal muscular atrophy. Sci. Transl. Med. 2010, 2:35ra42.
116. Van Meerbeke J.P., Gibbs R.M., Plasterer H.L., Miao W., Feng Z., Lin M.Y., Rucki A.A., Wee C.D., Xia B., Sharma S., Jacques V., Li D.K., Pellizzoni L., Rusche J.R., Ko C.P., Sumner C.J. The DcpS inhibitor RG3039 improves motor function in SMA mice. Hum. Mol. Genet. 2013, 22:4074-4083.
117. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3. (research0034.1-research0034.11).
118. Viollet L., Bertrandy S., Beuno Brunialti A.L., Lefebvre S., Burlet P., Clermont O., Cruaud C., Guénet J.L., Munnich A., Melki J. cDNA isolation, expression and chromosomal localization of the mouse survival motor neuron gene (Smn). Genomics 1997, 40:185-188.
119. Vitte J.M., Davoult B., Roblot N., Mayer M., Joshi V., Courageot S., Tronche F., Vadrot J., Moreau M.H., Kemeny F., Melki J. Deletion of murine Smn exon 7 directed to liver leads to severe defect of liver development associated with iron overload. Am. J. Pathol. 2004, 165:1731-1741.
120. Weihl C.C., Connolly A.M., Pestronk A. Valproate may improve strength and function in patients with type III/IV spinal muscular atrophy. Neurology 2006, 67:500-501.
121. Williams J.H., Schray R.C., Patterson C.A., Ayitey S.O., Tallent M.K., Lutz G.J. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J. Neurosci. 2009, 29:7633-7638.
122. Wirth B., Brichta L., Schrank B., Lochmüller H., Blick S., Baasner A., Heller R. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum. Genet. 2006, 119:422-428.
123. Woodgett J.R. Molecular cloning and expression glycogen synthase kinase-3/factor A. EMBO J. 1990, 9:2431-2438.
124. Ying M., Xu R., Wu X., Zhu H., Zhuang Y., Han M., Xu T. Sodium butyrate ameliorates histone hypoacetylation and neurodegenerative phenotypes in a mouse model for DRPLA. J. Biol. Chem. 2006, 281:12580-12586.
125. Young P.J., Le T.T., Nguyen thi Man, Burghes A.H.M., Morris G.E. The relationship between SMN, the spinal muscular atrophy protein, and nuclear coiled bodies in differentiated tissues and cultured cells. Exp. Cell Res. 2000, 256:365-374.
126. Zhang Z., Lotti F., Dittmar K., Younis I., Wan L., Kasim M., Dreyfuss G. SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell 2008, 133:585-600.
127. Zhou H., Janghra N., Mitrpant C., Dickinson R.L., Anthony K., Price L., Eperon I.C., Wilton S.D., Morgan J., Muntoni F. A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice. Hum. Gene Ther. 2013, 24:331-342.